BridgeBio Pharma, Inc.
BBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$543,347 | -$643,202 | -$484,652 | -$586,454 |
| Dep. & Amort. | $6,075 | $6,494 | $6,771 | $5,843 |
| Deferred Tax | $0 | $0 | $0 | -$30,930 |
| Stock-Based Comp. | $95,800 | $0 | $91,559 | $99,505 |
| Change in WC | $32,042 | $5,057 | $28,079 | -$4,396 |
| Other Non-Cash | -$111,296 | $103,931 | -$61,251 | $18,498 |
| Operating Cash Flow | -$520,726 | -$527,720 | -$419,494 | -$497,934 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$933 | -$1,306 | -$4,821 | -$48,246 |
| Net Acquisitions | -$140 | $0 | $0 | -$35,000 |
| Inv. Purchases | -$88,400 | -$137,264 | -$193,055 | -$643,275 |
| Inv. Sales/Matur. | $158,229 | $193,106 | $532,523 | $477,041 |
| Other Inv. Act. | -$7,975 | -$503 | $118,500 | $48,654 |
| Investing Cash Flow | $60,781 | $54,033 | $453,147 | -$200,826 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $476,583 | $0 | -$20,486 | $1,079,677 |
| Stock Issued | $314,741 | $449,810 | $4,852 | $0 |
| Stock Repurch. | -$7,526 | -$6,880 | -$1,561 | -$204,746 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$35,341 | $8,605 | $4,061 | -$138,485 |
| Financing Cash Flow | $748,457 | $451,535 | -$13,134 | $736,446 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $288,512 | -$22,152 | $20,519 | $37,686 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $394,732 | $416,884 | $396,365 | $358,679 |
| End Cash | $683,244 | $394,732 | $416,884 | $396,365 |
| Free Cash Flow | -$521,659 | -$529,026 | -$425,815 | -$546,180 |